Australia Takes Just Five Days To Approve Remdesivir For COVID-19
Executive Summary
The Therapeutic Goods Administration’s provisional approval for Gilead Sciences’ drug comes with a number of post-marketing obligations for the company.
You may also be interested in...
COVID-19: Gilead To Fill Remdesivir Supply Gap In EU
As the US firm prepares to ramp up production of the antiviral for use in coronavirus patients, a debate is growing over whether changes could be made to EU rules that prevent the importation of generic drugs produced under a compulsory license.
EU Approves Gilead’s Remdesivir For COVID-19 In Record Time
The EU has granted conditional marketing approval to Gilead’s drug, which has the brand name Veklury. It will cost about €2,000 per treatment.
New EU Filings
Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.